Biomarkers in Cardiovascular Disease—Chances and Risks, 2nd Volume

Dear Colleagues,

Although circulating and urinary biomarkers are now widely involved in the risk stratification and diagnosis of a wide range of cardiovascular diseases, ranging from acute coronary syndrome to any heart failure phenotypes, their predictive abilities and guided-treatment options remain to be determined. However, there is a large body of novel biomarker-guided approaches, such as micro-RNAs, pro- and anti-inflammatory cytokines, adipocytokines, myokines, cargo of secretom, metabolomics profile, extracellular vesicle labeling, etc., which are related to the prediction of adverse cardiac structural and electrophysiological remodeling, arrhythmia, thrombotic complications, heart failure, cardiorenal syndrome, pulmonary hypertension, etc. These approaches open new promising perspectives for personifying the management of cardiovascular disease in varied populations such as obesity- and diabetes mellitus-affected patients, individuals with malignancy under chemotherapy, patients with inherited and acquired cardiac defects, etc. This Topic will highlight new insights into the future diagnostic, predictive, and therapeutic potencies of biomarkers of cardiovascular diseases, as well as improve our understanding of the underlying molecular mechanisms of cardiovascular disease. Original articles, narrative and systemic reviews, meta-analyses, case reports, letters to editors, and short communications are all invited.

Prof. Dr. Alexander E. Berezin
Prof. Dr. Michael Lichtenauer
Topic Editors